These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 24874457)

  • 1. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study.
    Jauregui-Amezaga A; López-Cerón M; Aceituno M; Jimeno M; Rodríguez de Miguel C; Pinó-Donnay S; Zabalza M; Sans M; Ricart E; Ordás I; González-Suárez B; Cuatrecasas M; Llach J; Panés J; Pellise M
    Inflamm Bowel Dis; 2014 Jul; 20(7):1187-93. PubMed ID: 24874457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Garcia-Planella E; Mañosa M; Chaparro M; Beltrán B; Barreiro-de-Acosta M; Gordillo J; Ricart E; Bermejo F; García-Sánchez V; Piqueras M; Llaó J; Gisbert JP; Cabré E; Domènech E;
    Scand J Gastroenterol; 2018 Feb; 53(2):152-157. PubMed ID: 29189092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
    De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
    Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
    Kristensen V; Klepp P; Cvancarova M; Røseth A; Skar V; Moum B
    J Crohns Colitis; 2015 Feb; 9(2):164-9. PubMed ID: 25518057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study.
    Shimoyama T; Yamamoto T; Umegae S; Matsumoto K
    BMC Gastroenterol; 2018 Aug; 18(1):120. PubMed ID: 30068300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.
    Burri E; Beglinger C; von Felten S; Lehmann FS
    Dig Dis Sci; 2015 Feb; 60(2):485-91. PubMed ID: 25344905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
    Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study.
    Keshteli AH; van den Brand FF; Madsen KL; Mandal R; Valcheva R; Kroeker KI; Han B; Bell RC; Cole J; Hoevers T; Wishart DS; Fedorak RN; Dieleman LA
    World J Gastroenterol; 2017 Jun; 23(21):3890-3899. PubMed ID: 28638229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis.
    Amiriani T; Besharat S; Dadjou M; Roshandel G; Mirkarimi H; Salamat F; Joshaghani H
    Gastroenterol Nurs; 2018; 41(3):201-205. PubMed ID: 29847394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis.
    Yamaguchi S; Takeuchi Y; Arai K; Fukuda K; Kuroki Y; Asonuma K; Takahashi H; Saruta M; Yoshida H
    J Gastroenterol Hepatol; 2016 Jan; 31(1):93-8. PubMed ID: 26212346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission.
    Guardiola J; Lobatón T; Rodríguez-Alonso L; Ruiz-Cerulla A; Arajol C; Loayza C; Sanjuan X; Sánchez E; Rodríguez-Moranta F
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1865-70. PubMed ID: 24993368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.